Vol. 8, No 4: 110–117.

Medical Sciences

 2023

Scientific article

UDK 616.13-08
pdf-version

Nikol Alex Marchenko
specialist degree, Petrozavodsk State University
(Petrozavodsk, Russia),
nikolmarch17@gmail.com

New Aspects of Treatment of Atherosclerosis as an Inflammatory Disease: A Review

Scientific adviser:
Viktoria A. Korneva
Reviewer:
Aleksandr A. Ivshin
Paper submitted on: 11/11/2023;
Accepted on: 11/28/2023;
Published online on: 12/01/2023.
 Abstract. Cardiovascular disease is the leading cause of death worldwide. Despite the success of modern therapies for atherosclerosis (AS), there are still patients with residual risk. To develop new therapies, AS has come to be viewed as an inflammatory disease in which inflammasomes play a key role. The purpose of this article is to conduct a literature review on the importance of inflammasomes in AS and a new therapy for AS. Clinical trials are currently showing the efficacy of new treatments, but more research is needed to fully address this concept.
Keywords: atherosclerosis, inflammasome, interleukin 1ß, NLRP-3, canakinumab, residual risk

For citation: Marchenko, N. New Aspects of Treatment of Atherosclerosis as an Inflammatory Disease: A Review. StudArctic forum. 2023, 8 (4): 110–117.

References

Klinov V.V. New mechanisms of natural immunity: NLRP3 inflammasome. Department of Immunology and Allergology. Siberian State Medical University. URL: http://ssmu.immunology.sibhost.ru/IM/inflammasome_ru.html  (Accessed: 07.11.2023) (In Russ.)

Nasonov E.L., Popkova T.V. Anti-inflammatory therapy for atherosclerosis: contribution of and lessons of rheumatology. Rheumatology Science and Practice, 2017, No. 55 (5), pp. 465-473. (In Russ.)

Broz P., Dixit V.M. Inflammasomes: mechanism of assembly, regulation and signalling. Nature Reviews Immunology, 2016, No. 16 (7), pp. 407-420.

Getz G.S., Reardon C.A. Use of mouse models in atherosclerosis research. Methods in Mouse Atherosclerosis, 2015, No. 1339, pp. 1-16.

Hansson G.K., Libby P., et al. Inflammation and plaque vulnerability. Journal of Internal Medicine, 2015, No. 278 (5), pp. 483-493.

Karasawa T., Takahashi M. Role of NLRP3 inflammasomes in atherosclerosis. Journal of Atherosclerosis and Thrombosis, 2017, No. 24 (5), pp. 443-451.

Ketelhuth D.F., Lutgens E., et al. Immunometabolism and atherosclerosis: perspectives and clinical significance: a position paper from the Working Group on Atherosclerosis and Vascular Biology of the European Society of Cardiology. Cardiovascular Research, 2019, No. 115 (9), pp. 1385-1392.

Ridker P.M., Howard C.P., et al. Effects of interleukin-1β inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. Circulation, 2012, No. 126 (23), pp. 2739-2748.

Ridker P.M., Everett B.M., et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. New England Journal of Medicine, 2017, No. 377 (12), pp. 1119-1131.

Shao B.Z., Xu H.Y., et al. NLRP3 inflammasome in atherosclerosis: putting out the fire of inflammation. Inflammation, 2023, No. 46 (1), pp. 35-46.

Silvis M.J., Demkes E.J., et al. Immunomodulation of the NLRP3 inflammasome in atherosclerosis, coronary artery disease, and acute myocardial infarction. Journal of Cardiovascular Translational Research, 2021, No. 14, pp. 23-34.

Zhang Y., Li X., et al. Coronary endothelial dysfunction induced by nucleotide oligomerization domain-like receptor protein with pyrin domain containing 3 inflammasome activation during hypercholesterolemia: beyond inflammation. Antioxidants & Redox Signaling, 2015, No. 22 (13), pp. 1084-1096.

Displays: 1096; Downloads: 461;